Background: We previously reported an association between rs2660753, a prostate cancer susceptibility polymorphism, and invasive epithelial ovarian cancer (EOC; OR ¼ 1.2, 95% CI¼ 1.0-1.4, P trend ¼ 0.01) that showed a stronger association with the serous histological subtype (OR ¼ 1.3, 95% CI ¼ 1.1-1.5, P trend ¼ 0.003).
Introduction
Invasive epithelial ovarian cancer (EOC) has a recognized genetic component, but known high penetrance genes, such as BRCA1 and BRCA2, explain less than 10% of EOC risk (1) . The remaining unexplained risk is probably caused by a combination of multiple low to moderate penetrance genetic variants (2) .
We previously reported an association between rs2660753 on chromosome 3p12 and invasive EOC (OR ¼ 1.2, 95% CI ¼ 1.0-1.4, P trend ¼ 0.01, 1,973 cases/3,419 controls) that showed a stronger association with the serous histological subtype (OR ¼ 1.3, 95% CI ¼ 1.1-1.5, P trend ¼ 0.003, 901 cases/3,303 controls; ref. 3) . rs2660753 is a prostate cancer susceptibility polymorphism identified from a genome-wide association study of Europeans (4) and replicated in independent populations of European (5) and non-European (6) ancestry. The nearest genes (70-198 kb away) to rs2660753, VGLL3, CHMP2B, and Pit-1/POU1F1, encode proteins with potential roles in tumorigenesis (3) and the 3p12.3-pcen region has been identified as a candidate tumor suppressor gene locus (7) .
In this investigation, we sought to replicate the association between rs2660753 and invasive EOC in a larger sample of 12 additional studies from the international Ovarian Cancer Association Consortium (OCAC) comprising 4,482 cases and 6,894 controls.
Materials and Methods

Study population
Sixteen ovarian cancer case-control studies contributed data to this analysis. Four of the studies were included in (8) . Each study received ethics committee approval and all study subjects provided informed written consent. Pathologic and questionnaire data included tumor behavior, histology, age at diagnosis (or comparable date for controls), family history of breast or ovarian cancer and ethnicity/race.
Genotyping
Genotyping was carried out by using the 5 0 nuclease Taqman allelic discrimination assay (Applied Biosystems), except the Australian Ovarian Cancer Study and the Australian Cancer Study-Ovarian Cancer that used the Sequenom iPLEX protocol (Sequenom Inc.), and by using similar conditions as the original study (3). Consistency across laboratories was assessed by genotyping a common set of 95 DNAs (90 CEPH trios and 5 duplicate samples) with 98% or more concordance in genotype calls. Details of OCAC's criteria for acceptable genotyping have been described previously (8) .
Statistical analysis
Analyses were restricted to white non-Hispanic subjects. We excluded cases with non-EOC and borderline tumors. Genotypes of participants were used to estimate allele frequencies and departure from Hardy-Weinberg equilibrium (HWE) was assessed in controls by by using a chi-squared test. Single nucleotide polymorphism associations were evaluated by using unconditional logistic regression under ordinal and codominant genetic models to estimate ORs and 95% CIs. Statistical models were adjusted for age (<40, 40-49, 50-59, 60-69, and 70 years) in study-specific analyses and for age and study in combined analyses. Prior to pooling, tests of heterogeneity in ORs across studies were conducted by using the likelihood ratio test comparing models with and without a product term for genotype and study. Statistical tests were implemented with SAS software (SAS Institute).
Results
Genotype distributions for controls in all the studies were consistent with HWE (Table 1) . No evidence for an association was observed at rs2667053 in the replication set (OR ¼ 1.0, 95% CI ¼ 0.9-1.1, P trend ¼ 0.61 for all 4,482 cancers and OR ¼ 1.0, 95% CI ¼ 0.9-1.1, P trend ¼ 0.85 for 2,515 serous cancers) or in the combined discovery and replication sets (OR ¼ 1.0, 95% CI ¼ 1.0-1.1, P trend ¼ 0.28 for all 6,450 cancers and OR ¼ 1.1, 95% CI ¼ 1.0-1.2, P trend ¼ 0.11 for 3,563 serous cancers) under the ordinal model (Fig. 1) . No statistically significant associations were observed under the codominant model (data not shown). There was no statistical heterogeneity in ORs for all ovarian cancers or serous cancers when the discovery and replication sets were combined (P heterogeneity > 0.10). Figure 1 . Funnel plot of studyspecific and summary OR and 95% CI for the association between rs2660753 and serous ovarian cancer among white nonHispanic subjects in OCAC studies by using the ordinal genetic risk model. Squares (&) indicate study-specific OR; the size of squares is proportional to study-specific sample size; the width of lines (-) indicate the study-specific 95% CI; diamonds (¤) indicate summary OR; and the width of diamonds indicate summary 95% CI. Refer to footnote of Table 1 for study nomenclature.
Analyses stratified by family history of breast or ovarian cancer in first-degree relatives did not show statistically significant associations for all cancers (OR ¼ 0.9, P ¼ 0.67, 481 cases with family history and OR ¼ 1.0, P ¼ 0.81, 1,576 cases without family history) or for serous cancers (OR ¼ 1.1, P ¼ 0.70, 297 cases with family history and OR ¼ 1.0, P ¼ 0.93, 928 cases without family history).
Discussion
Our findings, based on 12 studies participating in the international OCAC, do not support an association between rs2667053 and invasive EOC overall or for the serous histological type. We used a larger sample size and applied similar assays and stringent quality control criteria to genotype data as in the original study. In the current study, the power to detect an OR of 1.2, as previously reported (3), with minor allele frequency of 0.12 and Type 1 error of 0.01 was 87%. To detect smaller effects, as observed for serous cancers in the current study, a much larger sample is required. There was no evidence of statistical heterogeneity in ORs across studies or of effect modification by family history. Although variant rs2667053 is a strong candidate for prostate cancer susceptibility, it does not seem to be a candidate risk factor for ovarian cancer.
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